secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001437749-26-000437
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex reports positive preclinical GPX-002 data in T2D; first NHP achieved normal glucose tolerance at 7 months
--------------------------------------------------------------------------------

- First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.
- Second NHP via direct pancreas injection improved glucose tolerance at 3 months but did not reach normal levels.
- T2D mice treated with GPX-002 showed reversal of hyperglycemia and normal glucose levels at 4 weeks post-surgery.
- GPX-002 aims to rejuvenate exhausted beta cells; company says data supports potential to address 90-95% of diabetes patients (T2D).
- Preclinical studies continuing; formal toxicology and IND submission planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/0001437749-26-000437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/gnpx20251201_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-000437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer